To evaluate safety and efficacy of weekly ( qw ) and every other week ( q@w ) dosing of sarilumab , a fully human anti-interleukin @ receptor ( anti-IL-@R ) monoclonal antibody , for moderate-to-severe rheumatoid arthritis ( RA ) .